Benned-Jensen Tau, Rosenkilde Mette M
Laboratory for Molecular Pharmacology, Department of Neuroscience and Pharmacology, The Panum Institute, Copenhagen University, Blegdamsvej 2, 2200 Copenhagen, Denmark.
Mol Pharmacol. 2008 Oct;74(4):1008-21. doi: 10.1124/mol.108.049676. Epub 2008 Jul 15.
The Epstein-Barr induced receptor 2 (EBI2) is a lymphocyte-expressed orphan seven transmembrane-spanning (7TM) receptor that signals constitutively through Galphai, as shown, for instance by guanosine 5'-O-(3-thio)triphosphate incorporation. Two regions of importance for the constitutive activity were identified by a systematic mutational analysis of 29 residues in EBI2. The cAMP response element-binding protein transcription factor was used as a measure of receptor activity and was correlated to the receptor surface expression. PheVI:13 (Phe257), and the neighboring CysVI:12 (Cys256), in the conserved CW/FxP motif in TM 6, acted as negative regulators as Ala substitutions at these positions increased the constitutive activity 5.7- and 2.3-fold, respectively, compared with EBI2 wild type (wt). In contrast, ArgII:20 (Arg87) in TM-2 acted as a positive regulator, as substitution to Ala, but not to Lys, decreased the constitutive activity more than 7-fold compared with wt EBI2. IleIII:03 (Ile106) is located only 4 A from ArgII:20, and a favorable electrostatic interaction with ArgII:20 was created by introduction of Glu in III:03, given that the activity increased to 4.4-fold of that wt EBI2. It is noteworthy that swapping these charges by introduction of Glu in II:20 and Arg in III:03 resulted in a 2.7-fold increase compared with wt EBI2, thereby rescuing the two signaling-deficient single mutations, which exhibited a 3.8- to 4.5-fold decrease in constitutive activity. The uncovering of these molecular mechanisms for EBI2 activation is important from a drug development point of view, in that it may facilitate the rational design and development of small-molecule inverse agonists against EBI2 of putative importance as antiviral- or immune modulatory therapy.
爱泼斯坦-巴尔病毒诱导受体2(EBI2)是一种淋巴细胞表达的孤儿七跨膜(7TM)受体,其通过Gαi组成性地发出信号,例如通过鸟苷5'-O-(3-硫代)三磷酸掺入来证明。通过对EBI2中29个残基的系统突变分析,确定了对组成性活性重要的两个区域。使用环磷酸腺苷反应元件结合蛋白转录因子作为受体活性的指标,并与受体表面表达相关。跨膜区6中保守的CW/FxP基序中的苯丙氨酸VI:13(Phe257)和相邻的半胱氨酸VI:12(Cys256)作为负调节因子,因为在这些位置用丙氨酸替代分别使组成性活性比EBI2野生型(wt)增加了5.7倍和2.3倍。相反,跨膜区2中的精氨酸II:20(Arg87)作为正调节因子,因为与wt EBI2相比,用丙氨酸替代(而不是赖氨酸)使组成性活性降低了7倍以上。异亮氨酸III:03(Ile106)距离精氨酸II:20仅4埃,并且通过在III:03中引入谷氨酸与精氨酸II:20形成了有利的静电相互作用,因为活性增加到了wt EBI2的4.4倍。值得注意的是,通过在II:20中引入谷氨酸和在III:03中引入精氨酸来交换这些电荷,与wt EBI2相比导致活性增加了2.7倍,从而挽救了两个信号缺陷的单突变,这两个单突变的组成性活性降低了3.8至4.5倍。从药物开发的角度来看,揭示这些EBI2激活的分子机制很重要,因为它可能有助于合理设计和开发针对EBI2的小分子反向激动剂,这些反向激动剂在抗病毒或免疫调节治疗中可能具有重要意义。